Literature DB >> 1557576

Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.

A L Gould1.   

Abstract

Monitoring clinical trials often requires examining the interim findings to see if the sample size originally specified in the protocol will provide the required power against the null hypothesis when the alternative hypothesis is true, and to increase the sample size if necessary. This paper presents a new method, based on the overall response rate, for carrying out interim power evaluations when the observations have binomial distributions, without unblinding the treatment assignments or materially affecting the type I error rate. Simulation study results confirm the performance of the method.

Mesh:

Year:  1992        PMID: 1557576     DOI: 10.1002/sim.4780110107

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

Review 1.  Multi-modality neuro-monitoring: conventional clinical trial design.

Authors:  Alexandros L Georgiadis; Yuko Y Palesch; David Zygun; J Claude Hemphill; Claudia S Robertson; Peter D Leroux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2015-06       Impact factor: 3.210

2.  Sample size re-estimation in a breast cancer trial.

Authors:  Erinn M Hade; David Jarjoura
Journal:  Clin Trials       Date:  2010-04-14       Impact factor: 2.486

3.  Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Authors:  Abdel G Babiker; Sean Emery; Gerd Fätkenheuer; Fred M Gordin; Birgit Grund; Jens D Lundgren; James D Neaton; Sarah L Pett; Andrew Phillips; Giota Touloumi; Michael J Vjechaj
Journal:  Clin Trials       Date:  2012-04-30       Impact factor: 2.486

4.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

5.  Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer.

Authors:  W M Gregory; K Bolland; J Whitehead; R L Souhami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Wearable Cardioverter-Defibrillator after Myocardial Infarction.

Authors:  Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Jerzy Wranicz; Rajesh Malik; Daniel P Morin; Steven Zweibel; Alfred E Buxton; Claude S Elayi; Eugene H Chung; Eric Rashba; Martin Borggrefe; Trisha F Hue; Carol Maguire; Feng Lin; Joel A Simon; Stephen Hulley; Byron K Lee
Journal:  N Engl J Med       Date:  2018-09-27       Impact factor: 91.245

7.  Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design.

Authors:  S Kasper; A Dienel; M Kieser
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

8.  An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.

Authors:  Michael Y Mi; Rebecca A Betensky
Journal:  Clin Trials       Date:  2013-01-02       Impact factor: 2.486

9.  Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial.

Authors:  Djillali Annane; Virginie Maxime; Jean Pierre Faller; Chaouki Mezher; Christophe Clec'h; Patricia Martel; Hélène Gonzales; Marc Feissel; Yves Cohen; Gilles Capellier; Miloud Gharbi; Olivier Nardi
Journal:  BMJ Open       Date:  2013-02-14       Impact factor: 2.692

10.  Sample size re-estimation in paired comparative diagnostic accuracy studies with a binary response.

Authors:  Gareth P J McCray; Andrew C Titman; Paula Ghaneh; Gillian A Lancaster
Journal:  BMC Med Res Methodol       Date:  2017-07-14       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.